BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Jan 8, 2025 · CIK: 882796
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K, likely with material news. Watch closely.
AI Summary
On January 8, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information that may be of interest to investors. No specific financial figures or new events were detailed in the provided excerpt, but the filing type suggests important updates were made.
Why It Matters
This filing indicates BioCryst Pharmaceuticals has made a disclosure under Regulation FD, which could contain material information relevant to investors.
Risk Assessment
Risk Level: medium — An 8-K filing often contains material information that can impact a company's stock price, requiring investor attention.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- January 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 62-1413174 (identifier) — IRS Employer Identification No.
- 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703 (address) — Principal Executive Offices
- (919) 859-1302 (phone_number) — Registrant's telephone number
FAQ
What specific information is being disclosed in this Regulation FD filing?
The provided excerpt does not detail the specific information disclosed under Regulation FD, only that the filing was made on January 8, 2025.
What is the primary purpose of an 8-K filing?
An 8-K filing is used by publicly traded companies to announce major corporate events that shareholders should know about.
When was BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal business address of BioCryst Pharmaceuticals?
The principal business address is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the IRS Employer Identification Number for BioCryst Pharmaceuticals?
The IRS Employer Identification Number for BioCryst Pharmaceuticals is 62-1413174.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-08 07:20:47
Key Financial Figures
- $42,366.03 — berotralstat) in the United States from $42,366.03 per 28-day pack (of either 150mg or 110
- $44,484.33 — (of either 150mg or 110mg capsules) to $44,484.33 per 28-day pack (of either 150mg or 110
Filing Documents
- f8k_010824.htm (8-K) — 21KB
- 0001171843-25-000112.txt ( ) — 189KB
- bcrx-20250108_lab.xml (EX-101.LAB) — 33KB
- bcrx-20250108_pre.xml (EX-101.PRE) — 22KB
- bcrx-20250108.xsd (EX-101.SCH) — 3KB
- f8k_010824_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Effective January 8, 2025, BioCryst Pharmaceuticals, Inc. (the "Company") is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO (berotralstat) in the United States from $42,366.03 per 28-day pack (of either 150mg or 110mg capsules) to $44,484.33 per 28-day pack (of either 150mg or 110mg capsules). The information in this Current Report on Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2025 BioCryst Pharmaceuticals, Inc. By: /s/ Alane Barnes Alane Barnes Chief Legal Officer